Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -199.29% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -45.66
Negative results in Jun 25
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Biotechnology
USD 601 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
14.95
-5,321.11%
203.02
Total Returns (Price + Dividend) 
MeiraGTx Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News

MeiraGTx Holdings Plc Announces Revision in Its Stock Evaluation Amid Financial Trends
MeiraGTx Holdings Plc has reported a notable increase in net sales for the quarter ending June 2025, alongside a decline in raw material costs, enhancing financial health. However, the company faces challenges with a significant net loss, low return on capital employed, and high debt-equity ratio, indicating potential financial strain.
Read More
MeiraGTx Holdings Hits New 52-Week High of $9.73, Up 78%
MeiraGTx Holdings Plc achieved a new 52-week high of USD 9.73 on November 10, 2025, reflecting a significant increase from its previous low. The company, with a market cap of USD 601 million, operates in the Pharmaceuticals & Biotechnology sector and is currently loss-making.
Read More
MeiraGTx Holdings Plc Stock Hits New 52-Week High of $9.44
MeiraGTx Holdings Plc has achieved a new 52-week high of USD 9.44, reflecting an impressive one-year performance of 82.08%. The company, with a market capitalization of USD 601 million, continues to face challenges, including a significant debt-to-equity ratio and ongoing losses.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Strategic Entities
Held in 31 Schemes (6.78%)
Held by 45 Foreign Institutions (18.16%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 94.74% vs -91.12% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 3.00% vs -1.52% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 137.86% vs -11.95% in Dec 2023
YoY Growth in year ended Dec 2024 is -75.95% vs 35.19% in Dec 2023






